CD27 and graft versus host disease: Contrary to this, another team investigating patients with chronic graft-versus-host disease (GVHD) demonstrated that treatment with MSCs led to an increase in the number of CD27 memory B cells and a decrease in plasma BAFF, associated with the increased expression of BAFF-R in peripheral B cells [42].